Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15 INK4B promoter demethylation in myelodysplastic syndrome

Gene Therapy

Volumn 22, Issue 4, 2015, Pages 287-296

  Ma, D ^a,b   Fang, Q ^a   Wang, P ^a,b   Gao, R ^a,b   Sun, J ^a   Li, Y ^a,b   Hu, X Y ^a,b   Wang, J S ^a,b  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Hematological Disease Diagnostic Treat Centre of GuiZhou Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN E; CYTOCHROME C; HEME OXYGENASE 1; LENTIVIRUS VECTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; AZACITIDINE; DECITABINE; ENZYME INHIBITOR; HMOX1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; UPREGULATION; ANALOGS AND DERIVATIVES; DNA METHYLATION; DRUG EFFECTS; METABOLISM; MITOCHONDRION; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

LENTIVIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HEME OXYGENASE-1; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; MYELODYSPLASTIC SYNDROMES; PROMOTER REGIONS, GENETIC; S PHASE CELL CYCLE CHECKPOINTS; YOUNG ADULT;

EID: 84926420785     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.1     Document Type: Article

References (41)

1. Ho J, de Guise C, Kim C, Lemay S, Wang XF, Lebrun JJ. Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1. Cell Signal 2004; 16: 693-701.
2. Fujiwara-Igarashi A, Goto-Koshino Y, Mochizuki H, Maeda S, Fujino Y, Ohno K et al. Simultaneous inactivation of the p16, p15 and p14 genes encoding cyclindependent kinase inhibitors in canine T-lymphoid tumor cells. J Vet Med Sci 2013; 75: 733-742.
3. Iordanskaia T, Nawshad A. Mechanisms of transforming growth factor beta induced cell cycle arrest in palate development. J Cell Physiol 2011; 226: 1415-1424.
4. Kiyota A, Shintani S, Mihara M, Nakahara Y, Ueyama Y, Matsumura T et al. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27 (KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 2002; 63: 92-98.
5. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J, Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-Positive non-Hodgkin's lymphomas. Am J Pathol 2002; 161: 1007-1013.
6. Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R. Methylation of INK4 and CIP/ KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J Clin Pathol 2006; 59: 921-926.
7. Lubbert M. Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes? Leukemia 2003; 17: 1762-1764.
8. Rodrigues EF, Santos-Reboucas CB, Goncalves Pimentel MM, Mencalha AL, Dobbin J, Da Costa ES et al. Epigenetic alterations of p15(INK4B) and p16(INK4A) genes in pediatric primary myelodysplastic syndrome. Leuk Lymphoma 2010; 51: 1887-1894.
9. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML et al. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 2005; 11: 4968-4976.
10. Papageorgiou SG, Lambropoulos S, Pappa V, Economopoulou C, Kontsioti F, Papageorgiou E et al. Hypermethylation of the p15INK4B gene promoter in B-chronic lymphocytic leukemia. Am J Hematol 2007; 82: 824-825.
11. Song LX, Xu L, Li X, Chang CK, Zhang Y, Wu LY et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol 2012; 91: 1879-1886.
12. Charlet J, Schnekenburger M, Brown KW, Diederich M. DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem Pharmacol 2012; 83: 858-865.
13. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987-1996.
14. Ritchie EK. Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome. Clin Interv Aging 2012; 7: 165-173.
15. Lubbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 2001; 114: 349-357.
16. Curik N, Burda P, Vargova K, Pospisil V, Belickova M, Vlckova P et al. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 2012; 26: 1804-1811.
17. Morales-Ramirez P, Vallarino-Kelly T, Cruz-Vallejo VL. Mechanisms of DNA breaks induction in vivo by 5-azacytidine: paths of micronucleus induction by azaC. J Appl Toxicol 2008; 28: 254-259.
18. Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 2007; 9: 2099-2117.
19. Alam J, Shibahara S, Smith A. Transcriptional activation of the heme oxygenase gene by heme and cadmium in mouse hepatoma cells. J Biol Chem1989; 264: 6371-6375.
20. Stuhlmeier KM. Activation and regulation of Hsp32 and Hsp70. Eur J Biochem 2000; 267: 1161-1167.
21. Vara D, Wheeler-Jones C, Mace K, Mellor H, Pula G. 531Platelet-derived deoxyribose-1-phosphate promotes endothelial cell motility and angiogenesis in vivo via redox stimulation. Cardiovasc Res 2014; 103: S97.
22. Foresti R, Clark JE, Green CJ, Motterlini R. Thiol compounds interact with nitric oxide in regulating heme oxygenase-1 induction in endothelial cells. Involvement of superoxide and peroxynitrite anions. J Biol Chem 1997; 272: 18411-18417.
23. Terry CM, Clikeman JA, Hoidal JR, Callahan KS. Effect of tumor necrosis factor-alpha and interleukin-1 alpha on heme oxygenase-1 expression in human endothelial cells. Am j physiol 1998; 274: H883-H891.
24. Jozkowicz A, Huk I, Nigisch A, Weigel G, Weidinger F, Dulak J. Effect of prostaglandin-J(2) on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxid Redox Signal 2002; 4: 577-585.
25. Zhang WL, Tsuneishi S, Nakamura H. Induction of heat shock proteins and its effects on glial differentiation in rat C6 glioblastoma cells. Kobe J Med Sci 2001; 47: 77-95.
26. Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier C et al. Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol 2006; 169: 2181-2198.
27. Nuhn P, Kunzli BM, Hennig R, Mitkus T, Ramanauskas T, Nobiling R et al. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol Cancer 2009; 8: 37.
28. Kuroda H, Takeno M, Murakami S, Miyazawa N, Kaneko T, Ishigatsubo Y. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 2010; 67: 31-36.
29. Miyazaki T, Kirino Y, Takeno M, Samukawa S, Hama M, Tanaka M et al. Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci 2010; 101: 1409-1416.
30. Miyake M, Fujimoto K, Anai S, Ohnishi S, Nakai Y, Inoue T et al. Clinical significance of heme oxygenase-1 expression in non-muscle-invasive bladder cancer. Urol Int 2010; 85: 355-363.
31. Su ZY, Shu L, Khor TO, Lee JH, Fuentes F, Kong AN. A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomics. Top Curr Chem 2013; 329: 133-162.
32. Jones PA. At the tipping point for epigenetic therapies in cancer. J Clin Invest 2014; 124: 14-16.
33. Valdespino-Gomez VM, Valdespino-Castillo VE. [Targeted epigenetic therapy of cancer. Achievements and perspectives]. Cir Cir 2012; 80: 470-480.
34. Muller CI, Ruter B, Koeffler HP, Lubbert M. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Curr Pharm Biotechnol 2006; 7: 315-321.
35. Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C et al. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technol Assess 2010; 14: 69-74.
36. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
37. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604-3608.
38. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and-negative myeloid leukemia cell lines. Leuk Res 2007; 31: 497-506.
39. Issa JP, Kantarjian HM., Targeting DNA. methylation. Clin Cancer Res 2009; 15: 3938-3946.
40. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573-586.
41. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-2964.